Table 4. Cost analysis: Mean cost per patient/year over study follow-up (VKA: VKA Group—NOAC: NOAC Group).
| VKA alone | NOAC alone | Switch | |||
|---|---|---|---|---|---|
| patients on VKA | patients on NOAC | patients on VKA+NOAC | |||
| N of patients | 1,355 | 577 | 239 | 239 | 239 |
| Drug, € | |||||
| Mean | 17.7 | 767.9 | 19.1 | 762.5 | 386.9 |
| SD | 13.6 | 171.3 | 12.0 | 159.9 | 166.5 |
| Median | 16.8 | 755.0 | 18.0 | 748.2 | 374.8 |
| Q1 | 10.8 | 683.9 | 10.5 | 674.5 | 260.5 |
| Q3 | 23.1 | 846.8 | 26.7 | 845.7 | 507.1 |
| Specialist Visits and Lab Tests, € | |||||
| Mean | 733.4 | 318.4 | 253.6 | 408.6 | 233.8 |
| SD | 8,559.3 | 326.0 | 602.2 | 432.2 | 164.0 |
| Median | 207.5 | 207.0 | 118.9 | 267.4 | 194.2 |
| Q1 | 133.8 | 110.9 | 57.4 | 151.7 | 125.0 |
| Q3 | 321.7 | 414.4 | 264.2 | 501.6 | 297.8 |
| ER Visits, € | |||||
| Mean | 9.6 | 6.6 | 41.6 | 8.1 | 24.2 |
| SD | 38.4 | 33.5 | 295.0 | 60.3 | 153.4 |
| Median | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Q1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Q3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hospital admissions, € | |||||
| Mean | 242.5 | 231.0 | 174.5 | 113.0 | 156.6 |
| SD | 1,046.6 | 1,127.6 | 722.8 | 599.8 | 561.2 |
| Median | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Q1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Q3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total per patient/year, € | |||||
| Mean | 1,003.3 | 1,323.9 | 488.8 | 1,292.1 | 801.5 |
| SD | 8,610.1 | 1,179.3 | 1,003.3 | 739.3 | 641.9 |
| Median | 260.1 | 1,040.6 | 174.5 | 1,076.2 | 642.3 |
| Q1 | 162.7 | 881.9 | 86.2 | 911.5 | 483.5 |
| Q3 | 444.5 | 1,276.7 | 416.9 | 1,421.0 | 845.7 |